

Looking for Someone to Guide You.Search Here!!!




- All Posts
- AMC

AUM ₹ 919,519.99 crore (as on 31-Mar-2024) No. of schemes 116…

AUM ₹ 3,56,286 Cr (As on Apr 2024) No. of schemes 106…

AUM ₹ 2,92,118 Cr (As on Apr 2024) No. of schemes…

AUM ₹ 145302 Cr (As on Dec 2023) No. of schemes…
Premium Listing

ARGHA CHOWDHURY
0.0Listings
Top Categories
Blogs
- April 30, 2026
- by admin
Top Investment Options India for Beginners
- April 14, 2026
- by admin
SIP vs Lump Sum Investment – Which is Better in India (2026 Guide)
- February 11, 2026
- by admin
Simple Ways To Improve Your Money Over Time
Market News
- Trent's Q2 margin, growth bring cheer. Can it sustain the momentum?
Margin expansion meant Trent’s Ebitda increased by almost 30% year-on-year, faster than the 22.5% growth in revenues to ₹5,788 crore. The Westside format is estimated to have delivered a better same-store sales growth.
- Sudarshan Pharma shares: Up 30% in 2026 so far! Will it rebound after profit-booking trigger? Experts' views, target, SL
Sudarshan Pharma share price has risen from ₹27 to ₹35.60 per share mark, delivering over 30% YTD returns to its shareholders
- Why Deepak Nitrite share price jumped 9% after Q2 results - Profit and other highlights | Check rating, stock returns
Deepak Nitrite shares opened at ₹1,580 per share on NSE today, as compared to previous close of ₹1,476 on Thursday and touched an intraday high of ₹1,615 apiece on 30 October.
- Crash! Why Equitas Small Finance Bank stock is so much down today? Share price plunges 12% despite strong Q2 - Reason?
Equitas Small Finance Bank shares fell nearly 12% for a second day, despite quarterly net profit rising to ₹218.03 crore. Investors reacted to CEO PN Vasudevan’s resignation amid conflict-of-interest concerns
- Laurus Labs share price at record high after Q2 results 2026, dividend announcement - Should you buy pharma stock?
Laurus Labs shares hit a record high after Q2FY27 revenue rose 33% and net profit jumped 126%. The company declared an interim dividend and expanded peptide manufacturing. While brokerages recognized growth prospects, they urged investors to weigh potential against the stock’s sharp rally.






































